Cibus (CBUS)
NASDAQ:CBUS
Top Page
Cibus
(NASDAQ:CBUS)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.00
▼(-29.58% Downside)
Action:ReiteratedDate:04/11/26
The score is held down primarily by weak financial performance (ongoing large losses, cash burn, and sharply reduced equity cushion). Technicals also remain bearish with the stock below major moving averages, despite oversold readings. Earnings-call updates add some offset from regulatory/commercial catalysts and extended runway, but near-term financing and execution risk remains high.
Positive Factors
Regulatory progress and market access
Substantive regulatory advances across major jurisdictions materially lower structural barriers to commercialization. Broad regulatory acceptance shortens time-to-market, increases addressable geography for partners, and improves likelihood that multi-year trait licensing and royalty streams can be realized across regions.
Negative Factors
Limited cash runway & cash burn
Even after the Jan‑2026 raise and cost cuts, runway into late‑2026 leaves the company dependent on delivering commercial milestones or securing additional financing. Persistent negative free cash flow and a narrow cash buffer create sustained dilution and execution risk over the next 6–12 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress and market access
Substantive regulatory advances across major jurisdictions materially lower structural barriers to commercialization. Broad regulatory acceptance shortens time-to-market, increases addressable geography for partners, and improves likelihood that multi-year trait licensing and royalty streams can be realized across regions.
Read all positive factors
Cibus (CBUS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$110.45M
Dividend YieldN/A
Average Volume (3M)154.04K
Price to Earnings (P/E)―
Beta (1Y)2.83
Revenue Growth-8.64%
EPS Growth85.68%
CountryUS
Employees157
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.59
Shares Outstanding76,172,870
10 Day Avg. Volume164,630
30 Day Avg. Volume154,044
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)36.47
Price to Sales (P/S)218.79
P/FCF Ratio-15.56
Enterprise Value/Market Cap2.93
Enterprise Value/Revenue88.91
Enterprise Value/Gross Profit371.89
Enterprise Value/Ebitda-5.26
Forecast
1Y Price Target
$14.67Price Target Upside933.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$8.02M
Cibus Business Overview & Revenue Model
Company Description
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yi...
How the Company Makes Money
null...
Cibus Earnings Call Summary
Earnings Call Date:Mar 17, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call conveyed substantial positive progress on technology performance, regulatory milestones, customer engagements, and near-term commercialization plans (especially for rice and sustainable ingredients). Management also executed meaningful cost reductions and secured a $22.3M financing to extend runway. Major challenges remain: the company is still loss-making with a Q4 net loss widened ~23.6%, royalty interest expense is significant, collaboration revenue timing weighed on results, and cash runway extends only into late 2026 absent further revenue or financing. Overall, the call emphasized execution and upcoming catalysts (EU plenary vote, Interox definitive agreement, Latin America field results) that support momentum but also highlighted the need to convert progress into cash flow in the near term.Positive Updates
Strong Commercial Momentum in Rice (RISE)
Seven RISE customers represent over $200 million in potential annual royalty opportunity; initial market entry targeted in Latin America in 2027, U.S. expansion in 2028, and India/Asia closer to 2030. Management is targeting 5–7 million acres in the Americas as initial scale.
Negative Updates
Widening Net Loss
Net loss was $31.9 million for the quarter ended 12/31/2025 versus $25.8 million year-ago, an increase of $6.1 million (≈23.6% higher), reflecting continuing operating losses despite cost reductions.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Commercial Momentum in Rice (RISE)
Seven RISE customers represent over $200 million in potential annual royalty opportunity; initial market entry targeted in Latin America in 2027, U.S. expansion in 2028, and India/Asia closer to 2030. Management is targeting 5–7 million acres in the Americas as initial scale.
Read all positive updates
Company Guidance
Cibus guided that it has $9.9M cash on hand (12/31/2025) and raised $22.3M gross in Jan‑2026, providing runway into late‑2026 (Q3) while targeting to cut annual net cash usage to ≈$30M or less in 2026 after ~ $10M of 2025 R&D/SG&A savings; Q4 expenses were R&D $9.4M, SG&A $5.1M, royalty interest $9.4M, and net loss $31.9M. Key commercial milestones: initial Latin America market entry targeted for 2027 (Interox LOI, definitive agreement expected late‑2026), potential U.S. expansion in 2028 and India/Asia around 2030, seven rice customers representing >$200M potential annual royalties targeting 5–7M acres in the Americas (India ≈120M acres could add ~another $200M), and a 12–15 month edit turnaround; sustainable ingredients/biofragrance commercialization and scale are expected near term (discussed a possible $20–$40M/year ramp). Regulatory catalysts highlighted include an EU NGT plenary vote expected late April 2026, UK PBO filings (submitted Jan), 17 USDA APHIS positive determinations, and favorable rulings in Ecuador and Peru.Cibus Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.64M | 4.26M | 1.82M | 157.00K | 25.99M |
| Gross Profit | -2.28M | 4.26M | 1.42M | -1.38M | -2.57M |
| EBITDA | -61.54M | -241.63M | -314.58M | -15.21M | -25.43M |
| Net Income | -127.08M | -251.39M | -267.63M | -16.89M | -29.20M |
Balance Sheet | |||||
| Total Assets | 305.05M | 350.07M | 544.41M | 22.42M | 37.19M |
| Cash, Cash Equivalents and Short-Term Investments | 9.92M | 14.43M | 32.70M | 3.43M | 13.82M |
| Total Debt | 267.96M | 36.29M | 24.62M | 13.91M | 17.88M |
| Total Liabilities | 283.22M | 252.24M | 206.12M | 15.19M | 23.06M |
| Stockholders Equity | 21.83M | 92.16M | 293.47M | 7.23M | 14.13M |
Cash Flow | |||||
| Free Cash Flow | -51.17M | -58.85M | -50.53M | -20.88M | -19.31M |
| Operating Cash Flow | -50.59M | -58.04M | -46.21M | -19.36M | -18.81M |
| Investing Cash Flow | -578.00K | -808.00K | 55.06M | -1.52M | 11.20M |
| Financing Cash Flow | 46.65M | 40.60M | 20.32M | 9.99M | 3.74M |
Cibus Technical Analysis
Negative
1.42
Price Trends
2.68
Negative
2.18
Negative
1.81
Negative
Market Momentum
-0.42
Positive
33.46
Neutral
24.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Negative. The current price of 1.42 is below the 20-day moving average (MA) of 2.11, below the 50-day MA of 2.68, and below the 200-day MA of 1.81, indicating a bearish trend. The MACD of -0.42 indicates Positive momentum. The RSI at 33.46 is Neutral, neither overbought nor oversold. The STOCH value of 24.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CBUS.
Cibus Risk Analysis
Cibus disclosed 50 risk factors in its most recent earnings report. Cibus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cibus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $37.13M | -2.65 | -96.04% | ― | -38.81% | -76.96% | |
48 Neutral | $375.50M | -2.14 | -115.27% | ― | 2925.73% | -294.29% | |
45 Neutral | $110.45M | -6.26 | -236.85% | ― | -8.64% | 85.68% | |
45 Neutral | $35.11M | -6.26 | -88.89% | ― | 56.52% | 75.22% | |
42 Neutral | $78.60M | -7.23 | ― | ― | ― | ― |
* Healthcare Sector Average
CBUS
Cibus
1.42
-0.19
-11.80%
CRVO
CervoMed
4.04
-5.45
-57.43%
XFOR
X4 Pharmaceuticals
4.20
-1.66
-28.33%
ABVC
ABVC BioPharma
1.36
0.39
40.21%
OKYO
OKYO Pharma Limited Sponsored ADR
1.58
0.45
39.82%
Cibus Corporate Events
Business Operations and StrategyExecutive/Board Changes
Cibus Strengthens Board with Appointment of Thomas Urban
Positive
Apr 10, 2026
On April 7, 2026, Cibus, Inc. appointed Thomas Urban, founder of Agribusiness Advisors and former chief executive of CellFor, Inc., to its Board of Directors, adding deep agribusiness, investment and global leadership experience to its governance....
Private Placements and Financing
Cibus Launches Underwritten Public Offering of Common Stock
Neutral
Mar 27, 2026
On March 25, 2026, Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for an underwritten public offering of 6,976,744 shares of its Class A common stock at $2.15 per share, with a 30-day option for the underwriter to purchase up to...
Private Placements and Financing
Cibus Announces Underwritten Public Offering of Common Stock
Neutral
Jan 30, 2026
On January 29, 2026, Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for an underwritten public offering of 13,333,333 shares of its Class A common stock at $1.50 per share, with company board members participating for 1,000,000 ...
Business Operations and StrategyFinancial Disclosures
Cibus streamlines operations to focus on rice traits
Positive
Jan 28, 2026
In 2025, Cibus undertook a significant operational streamlining to concentrate capital and resources on commercializing its weed management traits for rice, including a workforce reduction of about 34 employees approved in July 2025 and completed ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.